Jun 17, 2026
15 MIN READ

What Dose Do You Start Losing Weight on Wegovy?

Weight loss on semaglutide typically begins within 2–4 weeks of starting treatment, though individual results depend on dose progression and metabolic factors. PlexusDx helps identify your personalized response pathway through genetic testing.

GLP-1 weight loss starts at $129/mo Provider-reviewed options. No membership fees.

See if you qualify →

Jun 17, 2026
15 MIN READ

what dose do you start losing weight on wegovy? — PlexusDx GLP-1 education

Last reviewed: June 17, 2026

Last updated: June 17, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

Semaglutide activates GLP-1 receptors in the brain and gut, reducing appetite and slowing stomach emptying to create sustained satiety. Most patients notice measurable weight loss between weeks 2 and 4 of starting therapy, but the speed and magnitude of change depend on genetic factors, dose timing, and individual metabolic adaptation. Understanding your expected timeline helps set realistic goals and maintain motivation.

Timeline for Semaglutide Weight Loss Results

Weight loss momentum typically follows a predictable pattern during the first month of semaglutide treatment. Week 1 often brings appetite suppression and reduced food intake without significant scale movement, as your body adjusts to the medication's mechanism. By week 2, many patients report decreased hunger and begin losing 1–2 pounds weekly, a rate that often accelerates as doses increase during the titration phase.

The critical window for meaningful weight loss appears between weeks 3 and 8, when cumulative GLP-1 receptor activation produces sustained appetite reduction and metabolic changes. Clinical trial data showed participants losing an average of 5–10% body weight over 16 weeks on standard semaglutide protocols. However, genetic variations in GLP1R sensitivity mean some individuals experience earlier or more pronounced results, while others require longer adaptation periods.

How Dose Escalation Affects Weight Loss Speed

Semaglutide dosing follows a four-week titration schedule: starting at 0.25 mg weekly, then increasing to 0.5 mg, 1.0 mg, and finally 1.7 or 2.4 mg based on tolerance and response. Each dose increase triggers deeper GLP-1 receptor engagement, which typically intensifies appetite suppression and accelerates weight loss over the following 2–3 weeks. Patients often notice renewed appetite reduction 3–4 days after each dose increase, as the body's hunger signals respond to higher medication levels.

PlexusDx messaging emphasizes that your dose may need to go up, but your price won't—flat monthly pricing ($149/mo for Compounded Semaglutide Injection) removes financial barriers to reaching therapeutic doses. Rushing through the titration schedule does not guarantee faster weight loss; instead, slower escalation allows metabolic adaptation and reduces gastrointestinal side effects that can derail adherence. Finding your optimal maintenance dose (often 1.7–2.4 mg) typically takes 8–12 weeks.

Genetic Factors Influencing Semaglutide Response Speed

Individual differences in weight loss timing stem largely from genetic variation in the GLP1R gene and related appetite-regulation pathways. The GLP1R rs6923761 polymorphism alters receptor sensitivity, meaning patients with specific allele combinations may experience earlier or more robust appetite suppression than others on identical doses. Similarly, variants in the GIPR (glucose-dependent insulinotropic peptide receptor) gene influence how effectively semaglutide activates dual appetite pathways, affecting both speed and magnitude of weight loss.

PlexusDx Precision Peptide Genetic Test examines 14 metabolic pathways and 49 peptides to predict individual response patterns, helping patients understand whether they are likely to lose weight rapidly, gradually, or with plateau periods. The test identifies key variants in GLP1R rs6923761, GIPR rs1800437, FTO rs9939609, and MC4R rs17782313—markers that correlate with semaglutide sensitivity and weight loss trajectory. Adding genetic testing ($99 after your first month) transforms guesswork into personalized strategy, showing whether your genetics favor early or delayed response.

Realistic Weight Loss Expectations in the First Month

During the first 4 weeks on semaglutide, expect variable results: some patients lose 2–4 pounds in week 1 (mostly water and reduced food volume), while others see no scale change until week 3 or 4 despite clear appetite reduction. This variability frustrates many people, but it reflects normal adaptation to medication and individual metabolic rates. Focusing on non-scale wins—increased energy, less food noise, improved blood sugar control—during early weeks prevents discouragement when weight loss lags appetite suppression.

Plateau periods are common, occurring after 6–8 weeks as the body adapts to appetite suppression and dose levels. Rather than indicating treatment failure, plateaus signal that your current dose has reached its appetite-reduction ceiling; dose escalation typically restarts weight loss within 1–2 weeks. Clinical evidence shows that patients who reach their target maintenance dose (1.7–2.4 mg) and remain adherent continue losing weight gradually for 12–18 months, with total weight loss averaging 10–22% of starting body weight depending on baseline BMI and lifestyle factors.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

Will I lose weight in my first week on semaglutide?

Some patients notice 1–3 pounds of water weight loss in week 1 due to reduced food intake, but this does not reflect fat loss. Sustainable weight loss typically begins in week 2–3 as appetite suppression deepens and calorie deficit accumulates. PlexusDx patients starting Compounded Semaglutide Injection ($149/mo) report consistent appetite reduction by day 5–7, even before scale changes appear.

How much weight can I expect to lose in the first month?

Average first-month weight loss ranges from 2–8 pounds, depending on starting dose, individual metabolism, and adherence to reduced calorie intake. Patients starting at 0.25 mg typically lose less in month 1 than those beginning higher-dose protocols, but this reflects dose timing rather than medication ineffectiveness. Clinical trials show month 2–3 produce faster weight loss once doses reach 1.0–1.7 mg.

Does PlexusDx charge more if my semaglutide dose increases?

No. PlexusDx Compounded Semaglutide Injection maintains flat monthly pricing at $149/mo regardless of whether your dose increases from 0.25 mg to 2.4 mg. This pricing model removes financial disincentives to dose escalation and ensures you can reach your therapeutic dose without cost surprises.

What if I do not lose weight on semaglutide?

Non-response to semaglutide is rare but does occur; genetic factors in GLP1R and GIPR sensitivity explain most cases. PlexusDx Precision Peptide Genetic Test identifies whether your genetics predict strong or modest semaglutide response, helping determine if alternative compounds like Tirzepatide or dual GLP-Squared therapy may work better. Testing costs $99 after your first month and provides 150+ genetic insights across 14 metabolic pathways.

Can genetic testing predict my semaglutide weight loss timeline?

Yes. PlexusDx Precision Peptide Genetic Test examines GLP1R rs6923761 and 48 other peptide variants that influence appetite regulation speed and magnitude. Patients with certain allele combinations typically lose weight faster or experience deeper appetite suppression; the test results guide realistic expectations and help optimize your starting dose strategy for maximum early response.

Real prescribers. Published prices. No surprises.

Licensed providers in all 50 states. Online intake. No insurance, no membership required.

Start My Intake →

~60 seconds · $0 charged until your provider approves